Risk factors for second‐line dactinomycin failure after methotrexate treatment for low‐risk gestational trophoblastic neoplasia: a retrospective study

פריטים דומים

• Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease
  מאת: Dobson, L S, et al.
  יצא לאור: (2000)
• Phase III Trial of Weekly Methotrexate or Pulsed Dactinomycin for Low-Risk Gestational Trophoblastic Neoplasia: A Gynecologic Oncology Group Study
  מאת: Osborne, Raymond J., et al.
  יצא לאור: (2011)
• Are different methotrexate regimens as first line therapy for low risk gestational trophoblastic neoplasia more cost effective than the dactinomycin regimen used in GOG 0174?
  מאת: Miller, Caela R., et al.
  יצא לאור: (2016)
• Second Curettage for Low-Risk Nonmetastatic Gestational Trophoblastic Neoplasia
  מאת: Osborne, Raymond J, et al.
  יצא לאור: (2016)
• Treatment results of the second-line chemotherapy regimen for patients with low-risk gestational trophoblastic neoplasia treated with 5-day methotrexate and 5-day etoposide
  מאת: Kanno, Toshiyuki, et al.
  יצא לאור: (2018)